A Leland Albright1. 1. Department of Neurosurgery, University of Wisconsin Health Center, Room K4-836, 600 Highland Ave., Madison, WI 53792, USA. l.albright@neurosurg.wisc.edu
Abstract
INTRODUCTION: Intrathecal baclofen was first introduced in 1985 to manage childhood hypertonia. There has been an evolution in thought as to how candidates should be identified and what forms of hypertonia respond to this treatment. PURPOSE: This manuscript reviews the pharmacology of the drug, the assessment of candidates, the implantation of the infusion pump, and the usual doses delivered. Side effects and complications are reviewed as are outcomes.
INTRODUCTION: Intrathecal baclofen was first introduced in 1985 to manage childhood hypertonia. There has been an evolution in thought as to how candidates should be identified and what forms of hypertonia respond to this treatment. PURPOSE: This manuscript reviews the pharmacology of the drug, the assessment of candidates, the implantation of the infusion pump, and the usual doses delivered. Side effects and complications are reviewed as are outcomes.
Authors: Linda E Krach; Robert L Kriel; Richard C Gilmartin; Dale M Swift; Bruce B Storrs; Rick Abbott; John D Ward; Karen K Bloom; William H Brooks; Joseph R Madsen; John F McLaughlin; Joseph M Nadell Journal: Pediatr Rehabil Date: 2005 Jul-Sep
Authors: Neil Haranhalli; Dhanya Anand; Jeffrey H Wisoff; David H Harter; Howard L Weiner; Michelle Blate; Jonathan Roth Journal: Childs Nerv Syst Date: 2010-09-18 Impact factor: 1.475